KR20100040697A - Grs단백질 또는 이의 단편의 신규한 용도 - Google Patents
Grs단백질 또는 이의 단편의 신규한 용도 Download PDFInfo
- Publication number
- KR20100040697A KR20100040697A KR1020090096877A KR20090096877A KR20100040697A KR 20100040697 A KR20100040697 A KR 20100040697A KR 1020090096877 A KR1020090096877 A KR 1020090096877A KR 20090096877 A KR20090096877 A KR 20090096877A KR 20100040697 A KR20100040697 A KR 20100040697A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- grs
- protein
- glu
- leu
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12Y601/01014—Glycine-tRNA ligase (6.1.1.14)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (9)
- 서열번호 6으로 표시되는 아미노산 서열을 포함하는 폴리펩티드를 유효성분으로 함유하는 것을 특징으로 하는 항암용 조성물.
- 제1항에 있어서, 상기 폴리펩티드는 서열번호 1로 표시되는 아미노산 서열을 포함하는 것을 특징으로 하는 항암용 조성물.
- 제1항에 있어서, 상기 암은 유방암, 대장암, 폐암, 소세포폐암, 위암, 간암, 혈액암, 골암, 췌장암, 피부암, 두부 또는 경부암, 피부 또는 안구내 흑색종, 자궁암, 난소암, 직장암, 항문부근암, 결장암, 유방암, 나팔관암종, 자궁내막암종, 자궁경부암, 질암, 음문암종, 호지킨병, 식도암, 소장암, 내분비선암, 갑상선암, 부갑상선암, 부신암, 연조직 육종, 요도암, 음경암, 전립선암, 만성 또는 급성 백혈병, 림프구 림프종, 방광암, 신장암, 수뇨관 암, 신장세포 암종, 신장골반 암종, CNS종양, 1차 CNS 림프종, 척수 종양, 뇌간신경교종 및 뇌하수체 선종으로 구성된 군에서 선택되는 하나 이상인 것을 특징으로 하는 항암용 조성물.
- 제1항의 폴리펩티드를 암호화하는 핵산을 유효성분으로 함유하는 것을 특징으로 하는 항암용 조성물.
- 제5항에 있어서, 상기 핵산은 서열번호 2 또는 서열번호 7로 표시되는 염기 서열을 갖는 것을 특징으로 하는 항암용 조성물.
- 제5항에 있어서, 상기 핵산이 발현 벡터 내에 포함되어 있는 것을 특징으로 하는 항암용 조성물.
- 제7항에 있어서, 상기 발현 벡터가 플라스미드 또는 바이러스성 벡터인 것을 특징으로 하는 항암용 조성물.
- 제8항에 있어서, 상기 플라스미드가 pRK5, pSV16B, pVL1392 및 pcDNA3으로 이루어진 군에서 선택된 것을 특징으로 하는 항암용 조성물.
- 제8항에 있어서, 상기 바이러스성 벡터가 레트로바이러스 벡터, 아데노바이러스 벡터 및 허피스바이러스 벡터 중에서 선택되는 것을 특징으로 하는 항암용 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20080099784 | 2008-10-10 | ||
KR1020080099784 | 2008-10-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100040697A true KR20100040697A (ko) | 2010-04-20 |
KR101102485B1 KR101102485B1 (ko) | 2012-01-05 |
Family
ID=42101119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090096877A KR101102485B1 (ko) | 2008-10-10 | 2009-10-12 | Grs단백질 또는 이의 단편의 신규한 용도 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8901081B2 (ko) |
EP (1) | EP2351575B1 (ko) |
KR (1) | KR101102485B1 (ko) |
WO (1) | WO2010041913A2 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013055101A1 (en) * | 2011-10-10 | 2013-04-18 | Medicinal Bioconvergence Research Center | Method for screening an agent preventing or treating cancer using glycyl-trna synthetase and cadherin |
KR20140108774A (ko) * | 2013-02-28 | 2014-09-15 | 재단법인 의약바이오컨버젼스연구단 | 글라이실-tRNA 합성효소를 포함하는 마이크로베지클의 제조방법 |
US10258674B2 (en) | 2014-05-28 | 2019-04-16 | Medicinal Bioconvergence Research Center | Nanoparticles comprising aminoacyl tRNA synthetase and anticancer composition comprising same |
WO2019225899A1 (ko) * | 2018-05-23 | 2019-11-28 | 주식회사 큐어바이오 | 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도 |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2727622A1 (en) * | 2008-06-11 | 2009-12-17 | Atyr Pharma, Inc. | Thrombopoietic activity of tyrosyl-trna synthetase polypeptides |
JP5756751B2 (ja) | 2008-06-26 | 2015-07-29 | エータイアー ファーマ, インコーポレイテッド | 非正準的な生物学的活性を有するグリシル−tRNA合成酵素を含む組成物および方法 |
US20120004185A1 (en) | 2009-02-27 | 2012-01-05 | Atyr Pharma, Inc. | Polypeptide structural motifs associated with cell signaling activity |
CN104830812B (zh) | 2009-03-16 | 2017-09-05 | 盘古生物制药有限公司 | 包含具有非经典生物活性的组氨酰‑tRNA合成酶剪接变异体的组合物及方法 |
WO2010120509A2 (en) | 2009-03-31 | 2010-10-21 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities |
US20110150885A1 (en) * | 2009-12-11 | 2011-06-23 | Atyr Pharma, Inc. | Aminoacyl trna synthetases for modulating hematopoiesis |
WO2011072265A1 (en) | 2009-12-11 | 2011-06-16 | Atyr Pharma, Inc. | Aminoacyl trna synthetases for modulating inflammation |
US8828395B2 (en) | 2009-12-11 | 2014-09-09 | Atyr Pharma, Inc. | Antibodies that bind tyrosyl-tRNA synthetases |
WO2011139714A2 (en) | 2010-04-26 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
US8986681B2 (en) | 2010-04-27 | 2015-03-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases |
AU2011248614B2 (en) | 2010-04-27 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
WO2011139853A2 (en) | 2010-04-28 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
US9068177B2 (en) | 2010-04-29 | 2015-06-30 | Atyr Pharma, Inc | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
CA2797374C (en) | 2010-04-29 | 2021-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases |
EP2563383B1 (en) | 2010-04-29 | 2017-03-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
WO2011139986A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
CA2797977C (en) | 2010-05-03 | 2019-08-20 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases |
CN103108655B (zh) | 2010-05-03 | 2017-04-05 | Atyr 医药公司 | 与丝氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
JP6008841B2 (ja) | 2010-05-03 | 2016-10-19 | エータイアー ファーマ, インコーポレイテッド | メチオニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
EP2566499B1 (en) | 2010-05-04 | 2017-01-25 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
JP6008843B2 (ja) | 2010-05-04 | 2016-10-19 | エータイアー ファーマ, インコーポレイテッド | グルタミル−プロリルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
CA2799197C (en) | 2010-05-14 | 2019-10-29 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
CA2799480C (en) | 2010-05-17 | 2020-12-15 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases |
US8962560B2 (en) | 2010-06-01 | 2015-02-24 | Atyr Pharma Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases |
AU2011279392C1 (en) | 2010-07-12 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases |
CN103118695B (zh) * | 2010-07-12 | 2016-08-03 | Atyr医药公司 | 与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现 |
EP2593126B1 (en) | 2010-07-12 | 2017-09-20 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases |
US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
EP2608801B1 (en) | 2010-08-25 | 2019-08-21 | aTyr Pharma, Inc. | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES |
ES2645019T3 (es) | 2010-10-06 | 2017-12-01 | Atyr Pharma, Inc. | Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de triptofanil-ARNt sintetasas |
US9673102B2 (en) * | 2011-04-01 | 2017-06-06 | Micron Technology, Inc. | Methods of forming vertical field-effect transistor with self-aligned contacts for memory devices with planar periphery/array and intermediate structures formed thereby |
US20160144003A1 (en) * | 2011-05-19 | 2016-05-26 | The Scripps Research Institute | Compositions and methods for treating charcot-marie-tooth diseases and related neuronal diseases |
WO2013022982A2 (en) | 2011-08-09 | 2013-02-14 | Atyr Pharma, Inc. | Pegylated tyrosyl-trna synthetase polypeptides |
US9816084B2 (en) | 2011-12-06 | 2017-11-14 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetases |
WO2013086228A1 (en) | 2011-12-06 | 2013-06-13 | Atyr Pharma, Inc. | Pegylated aspartyl-trna synthetase polypeptides |
CN104220461A (zh) | 2011-12-29 | 2014-12-17 | Atyr医药公司 | 天冬氨酰-tRNA合成酶-FC缀合物 |
ES2652136T3 (es) | 2012-02-16 | 2018-01-31 | Atyr Pharma, Inc. | Histidil-tRNA sintetasas para tratar enfermedades autoinmunitarias e inflamatorias |
EP2970921B1 (en) | 2013-03-15 | 2018-09-19 | aTyr Pharma, Inc. | Histidyl-trna synthetase-fc conjugates |
WO2018195338A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
JPH05503003A (ja) | 1989-11-22 | 1993-05-27 | ジェネンテク,インコーポレイテッド | 潜在性関与ペプチドおよびその使用 |
US6506607B1 (en) * | 1997-12-24 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer |
CN1330144A (zh) | 2000-06-19 | 2002-01-09 | 上海博德基因开发有限公司 | 一种新的多肽——人I类氨酰基-tRNA合成酶10和编码这种多肽的多核苷酸 |
WO2003051382A1 (fr) | 2001-12-14 | 2003-06-26 | Sundory Co., Ltd. | Procédé d'induction d'apoptose et compositions pour cette dernière |
EP1369482A1 (en) * | 2002-06-07 | 2003-12-10 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Target genes for the diagnosis and treatment of cancer |
WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
JP5033471B2 (ja) | 2007-05-09 | 2012-09-26 | 住友化学株式会社 | 有機化合物の結晶およびその製造方法 |
JP5756751B2 (ja) * | 2008-06-26 | 2015-07-29 | エータイアー ファーマ, インコーポレイテッド | 非正準的な生物学的活性を有するグリシル−tRNA合成酵素を含む組成物および方法 |
-
2009
- 2009-10-12 KR KR1020090096877A patent/KR101102485B1/ko active IP Right Grant
- 2009-10-12 US US13/123,522 patent/US8901081B2/en active Active
- 2009-10-12 WO PCT/KR2009/005829 patent/WO2010041913A2/ko active Application Filing
- 2009-10-12 EP EP09819420.2A patent/EP2351575B1/en active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013055101A1 (en) * | 2011-10-10 | 2013-04-18 | Medicinal Bioconvergence Research Center | Method for screening an agent preventing or treating cancer using glycyl-trna synthetase and cadherin |
KR101398079B1 (ko) * | 2011-10-10 | 2014-05-27 | 재단법인 의약바이오컨버젼스연구단 | 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법 |
US9274113B2 (en) | 2011-10-10 | 2016-03-01 | Medicinal Bioconvergence Research Center | Method for screening an agent preventing or treating cancer using glycyl-tRNA synthetase and cadherin |
KR20140108774A (ko) * | 2013-02-28 | 2014-09-15 | 재단법인 의약바이오컨버젼스연구단 | 글라이실-tRNA 합성효소를 포함하는 마이크로베지클의 제조방법 |
US10258674B2 (en) | 2014-05-28 | 2019-04-16 | Medicinal Bioconvergence Research Center | Nanoparticles comprising aminoacyl tRNA synthetase and anticancer composition comprising same |
WO2019225899A1 (ko) * | 2018-05-23 | 2019-11-28 | 주식회사 큐어바이오 | 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도 |
KR20190133559A (ko) * | 2018-05-23 | 2019-12-03 | 주식회사 큐어바이오 | 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도 |
Also Published As
Publication number | Publication date |
---|---|
EP2351575B1 (en) | 2016-12-14 |
KR101102485B1 (ko) | 2012-01-05 |
EP2351575A4 (en) | 2013-04-03 |
WO2010041913A2 (ko) | 2010-04-15 |
US20110256119A1 (en) | 2011-10-20 |
EP2351575A2 (en) | 2011-08-03 |
WO2010041913A9 (ko) | 2010-10-07 |
US8901081B2 (en) | 2014-12-02 |
WO2010041913A3 (ko) | 2010-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101102485B1 (ko) | Grs단백질 또는 이의 단편의 신규한 용도 | |
JP4351896B2 (ja) | p38/JTV−1を有効成分とする癌治療用薬学的組成物及び癌治療用薬学的組成物のスクリーニング方法 | |
KR100747646B1 (ko) | 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물 | |
KR101215069B1 (ko) | Gkn 1을 함유하는 항암용 조성물 | |
Park et al. | Homeobox Msx1 interacts with p53 tumor suppressor and inhibits tumor growth by inducing apoptosis | |
JP5625143B2 (ja) | モータリンsiRNAを含む癌治療剤 | |
JP2020072716A (ja) | 細胞透過組成物およびそれを用いる方法 | |
KR20070011892A (ko) | Msx1 단백질 또는 이를 코딩하는 유전자를유효성분으로 포함하는 세포사멸유도제 | |
RU2636003C2 (ru) | Композиция для лечения рака, ассоциированного с инфекцией hpv | |
CN115786270A (zh) | 工程化的巨噬细胞及其在治疗纤维化疾病中的应用 | |
US20060040859A1 (en) | Peptides, DNAs, RNAs, and compounds for inhibiting or inducing adrenomedullin activity, and use of the same | |
WO2006106599A1 (ja) | 細胞外ドメインシェディングの異常亢進に起因する疾患の予防及び/又は治療のための医薬 | |
Li et al. | Toosendanin Restrains Idiopathic Pulmonary Fibrosis by Inhibiting ZEB1/CTBP1 Interaction | |
JP2020530844A (ja) | Setd2を阻害することにより癌を処置する方法 | |
KR101697771B1 (ko) | Itm2a 폴리펩타이드 또는 이를 암호화하는 핵산을 유효성분으로 하는 항암용 조성물 | |
KR101497930B1 (ko) | Hs2st1 유전자 또는 상기 유전자가 암호화하는 단백질에 대한 억제제를 포함하는 세포 노화 유도용 조성물 및 이를 이용한 세포 노화 유도 방법 | |
WO2011162419A1 (ja) | ガラクトシルセラミド発現因子-1を標的とする腫瘍増殖制御法 | |
KR100710550B1 (ko) | 피오에이치 1 유전자 또는 피오에이치 1 단백질을포함하는 암세포 성장 억제제, 이의 제조방법 및 이를이용한 암세포 증식 억제방법 | |
KR101542654B1 (ko) | Zmym2를 유효성분으로 함유하는 항암제 민감성 증진용 조성물 | |
KR20220074589A (ko) | miRNA-20b-5p 억제제를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물 | |
KR100710549B1 (ko) | 라민 에이 유전자 또는 라민 에이 단백질을 포함하는암세포 증식 억제제, 이의 제조방법 및 이를 이용한암세포 증식 억제방법 | |
CN115590880A (zh) | 工程化的巨噬细胞联用在治疗纤维化疾病中的应用 | |
KR20020088738A (ko) | 암세포 증식 억제 단백질 e2를 생산하는 재조합아데노바이러스 벡터 및 이의 용도 | |
KR20050098800A (ko) | 임포틴 α유전자 및/또는 재조합 p53 유전자를 포함하는항암제 | |
JP2006335659A (ja) | 癌細胞増殖抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141210 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20151126 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160222 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20171124 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181203 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191203 Year of fee payment: 9 |